Luminescent macrocyclic lanthanide complexes
View Patent ↗The present invention provides a novel class of macrocyclic compounds as well as complexes formed between a metal (e.g., lanthanide) ion and the compounds of the invention. Preferred complexes exhibit high stability as well as high quantum yields of lanthanide ion luminescence in aqueous media without the need for secondary activating agents. Preferred compounds incorporate hydroxy-isophthalamide moieties within their macrocyclic structure and are characterized by surprisingly low, non-specific binding to a variety of polypeptides such as antibodies and proteins as well as high kinetic stability. These characteristics distinguish them from known, open-structured ligands.
1. A compound having a structure according to Formula I:
wherein
said compound is covalently modified with at least one functional moiety;
each Z is a member independently selected from O and S;
L 1 , L 2 , L 3 , L 4 , L 5 , L 6 , L 7 , L 8 , L 9 and L 10 are linker groups independently selected from substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl and substituted or unsubstituted heterocycloalkyl;
A 1 , A 2 , A 3 and A 4 are members independently selected from the general structure:
wherein
each R 1 is a member independently selected from H, an enzymatically labile group, a hydrolytically labile group, a metabolically labile group and a single negative charge; and
each R 5 , R 6 and R 7 is a member independently selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, halogen, CN, CF 3 , acyl, —SO 2 NR 17 R 18 , —NR 17 R 18 , —OR 17 , —S(O) 2 R 17 , —COOR 17 , —S(O) 2 OR 17 , —OC(O)R 17 , —C(O)NR 17 R 18 , —NR 17 C(O)R 18 , —NR 17 SO 2 R 18 , and NO 2 ,
wherein
R 6 and a member selected from R 5 , R 7 and combinations thereof are optionally joined to form a ring system which is a member selected from substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl and substituted or unsubstituted heteroaryl,
R 17 and R 18 are members independently selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl and substituted or unsubstituted heterocycloalkyl, and R 17 and R 18 , together with the atoms to which they are attached, are optionally joined to form a 5- to 7-membered ring.
2. The compound according to claim 1 , having the structure:
wherein
R 1 , R 2 , R 3 and R 4 are members independently selected from H, an enzymatically labile group, a hydrolytically labile group, a metabolically labile group and a single negative charge; and
R 5 , R 6 , R 7 , R 8 , R 9 R 10 , R 11 , R 12 , R 13 , R 14 , R 15 and R 16 are members independently selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, halogen, CN, CF 3 , acyl, —SO 2 NR 17 R 18 , —NR 17 R 18 , —OR 17 , —S(O) 2 R 17 , —COOR 17 , —S(O) 2 OR 17 , —OC(O)R 17 , —C(O)NR 17 R 18 , —NR 17 C(O)R 18 , —NR 17 SO 2 R 18 , and —NO 2 ,
wherein
R 17 and R 18 are members independently selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl and substituted or unsubstituted heterocycloalkyl, wherein R 17 and R 18 , together with the atoms to which they are attached, are optionally joined to form a 5- to 7-membered ring;
R 6 and a member selected from R 5 , R 7 and combinations thereof are optionally joined to form a ring system;
R 9 and a member selected from R 8 , R 10 and combinations thereof are optionally joined to form a ring system;
R 12 and a member selected from R 11 , R 13 and combinations thereof are optionally joined to form a ring system,
wherein
said ring system is a member selected from substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl and substituted or unsubstituted heteroaryl.
3. The compound according to claim 1 , wherein at least one of L 1 , L 2 , L 3 , L 4 , L 5 , L 6 , L 7 , L 8 , L 9 , L 10 , A 1 , A 2 , A 3 and A 4 is substituted with a functional moiety.
4. The compound according to claim 1 , wherein said functional moiety has the structure:
wherein
L 11 is a linker moiety, which is a member selected from substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl and substituted or unsubstituted heteroaryl; and
X is a member selected from a reactive functional group and a targeting moiety.
5. The compound according to claim 4 , having a structure, which is a member selected from:
6. The compound according to claim 4 , wherein said targeting moiety comprises a member selected from a small-molecule ligand, a peptide, a protein, an enzyme, an antibody, an antigen, a nucleic acid, a carbohydrate, a lipid and a pharmacologically active molecule.
7. The compound according to claim 4 , wherein said targeting moiety is substituted with a luminescence modifying group allowing luminescence energy transfer between said complex and said luminescence modifying group when said complex is excited.
8. The compound according to claim 4 , wherein said reactive functional group is a member selected from —OH, —SH, —NH 2 , —C(O)NHNH 2 (hydrazide), maleimide, activated ester, aldehyde, ketone, hydroxylamine, imidoester, isocyanate, isothiocyanate, sulfonylchloride, acylhalide and —COOY, wherein Y is a member selected from H, a negative charge and a salt counter-ion.
9. The compound according to claim 4 , wherein X is NH 2 and L 11 is a member selected from substituted or unsubstituted C 1 to C 10 alkyl and substituted or unsubstituted C 1 to C 10 heteroalkyl.
10. The compound according to claim 4 , wherein said functional moiety comprises a polyether.
11. The compound according to claim 10 , wherein said polyether is a member selected from polyethylene glycol (PEG) and derivatives thereof.
12. The compound according to claim 11 , wherein said polyether has a molecular weight of about 50 to about 10,000 daltons.
13. The compound according to claim 1 , wherein said linker moieties L 1 , L 2 , L 3 , L 4 , L 5 , L 6 , L 7 , L 8 , L 9 and L 10 are members independently selected from substituted or unsubstituted C 1 to C 6 alkyl.
14. The compound according to claim 13 , wherein said linker moieties L 1 , L 2 , L 3 , L 4 , L 5 , L 6 , L 7 , L 8 , L 9 and L 10 are members independently selected from substituted or unsubstituted ethyl.
15. A luminescent complex formed between at least one metal ion and a compound according to claim 1 .
16. The complex according to claim 15 , wherein said metal ion is a lanthanide ion.
17. The complex according to claim 16 , wherein said lanthanide is a member selected from neodynium (Nd), samarium (Sm), europium (Eu), terbium (Tb), dysprosium (Dy) and ytterbium (Yb).
18. A method of detecting the presence of an analyte in a sample, said method comprising:
(a) contacting said sample and a composition comprising a luminescent complex according to claim 15 ,
(b) exciting said complex; and
(c) detecting luminescence from said complex.
19. A method of detecting the presence of an analyte in a sample, said method comprising:
(a) contacting said sample and a composition comprising a luminescent complex according to claim 15 and a luminescence modifying group, wherein energy can be transferred between said luminescent complex and said luminescence modifying group when said complex is excited, and wherein said complex and said luminescence modifying group can be part of the same molecule or be part of different molecules;
(b) exciting said complex; and
(c) determining the luminescent property of said sample, wherein the presence of said analyte results in a change in said luminescent property.
20. The method according to claim 19 , wherein said analyte, if present in said sample, binds to an antibody, wherein said antibody is covalently linked to a member selected from a luminescence modifying group and a complex according to claim 15 .
21. The method according to claim 20 , wherein said analyte is a lipid.